SequelSEC

BeOne Medicines Ltd. ONC

Pharmaceutical Preparations · CIK 0001651308 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$6.13B
Fiscal year ended 2026-06-30
Operating income
$923.10M
Fiscal year ended 2026-06-30
Free cash flow
$1.33B
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$14.70BMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$10.19Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / net income51.2×A lower bound on the multiple, because affiliate holdings are excluded.
Float / revenue2.8×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity3.4×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
FCF margin17.6%85th
Operating margin8.4%83th
Effective tax rate31.2%81th
Net margin5.4%80th
Gross margin87.5%79th
Revenue YoY growth40.2%72th
R&D / revenue40.2%32th
Long-term debt / equity0.22x33th
SBC / revenue9.6%34th
CapEx / revenue3.5%61th
Current ratio3.41x46th

BeOne Medicines Ltd. (ONC) reported revenue of $6.13B and net income of $655.71M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from BeOne Medicines Ltd.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

BeOne Medicines Ltd. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$6.13B
Cost of revenueUnavailable
Gross profit$5.45B
Operating income$923.10M
Net income$655.71M
Research & development$2.29B
Weighted-average diluted sharesUnavailable
Pretax income$868.08M
Income tax expense$212.37M
Diluted EPSUnavailable
Selling, general & administrative$2.23B
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

BeOne Medicines Ltd. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$5.10B
Total assets$9.18B
Current assets$7.22B
Total liabilities$4.00B
Current liabilities$2.12B
Total equity incl. NCI$5.17B
Temporary (mezzanine) equityUnavailable
Inventory$732.60M
Accounts receivable$1.06B
GoodwillUnavailable
Long-term debt$882.16M
Accounts payable$470.30M

Cash flow

BeOne Medicines Ltd. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$1.48B
Capital expenditures$153.87M
Investing cash flow-$182.47M
Financing cash flow$1.12B
Net change in cash$2.49B
Stock-based compensation$525.33M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$154.93M

Derived

BeOne Medicines Ltd. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow$1.33B
Gross margin88.9%
Operating margin15.1%
FCF margin21.7%
SBC / revenue8.6%
Current ratio3.40x
Revenue YoY growth34.3%
Net margin10.7%
R&D / revenue37.4%
CapEx / revenue2.5%
Long-term debt / equity0.17x
Effective tax rate24.5%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ONC in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-05View SEC filing
10-Q · Filed 2026-05-06View SEC filing
10-K · Filed 2026-02-26View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-06View SEC filing
10-Q · Filed 2025-05-07View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.